

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

**RESIGNATION OF NON-EXECUTIVE DIRECTOR;
RESIGNATION OF CHIEF EXECUTIVE OFFICER;
AND
CHANGE OF CHAIRMAN OF THE BOARD,
CHAIRMAN OF THE NOMINATION COMMITTEE AND
MEMBERS OF THE CORPORATE GOVERNANCE COMMITTEE**

The Board hereby announces that, with effect from 29 August 2024, (1) Mr. Han Yuewei has resigned as chairman of the Board, a non-executive Director and chairman of the Nomination Committee; (2) Mr. Bai Xiaosong, currently an executive Director and Chief Executive Officer, has been appointed as the chairman of the Board and the chairman of the Nomination Committee, and has resigned as the Chief Executive Officer and a member of the Corporate Governance Committee; and (3) Ms. Deng Rong, currently an executive Director and Chief Financial Officer, has been appointed as a member of the Corporate Governance Committee.

**RESIGNATION OF CHAIRMAN OF THE BOARD, NON-EXECUTIVE DIRECTOR
AND CHAIRMAN OF THE NOMINATION COMMITTEE**

The board (the “**Board**”) of directors (the “**Director(s)**”) of China Resources Pharmaceutical Group Limited (the “**Company**”) hereby announces that, with effect from 29 August 2024, Mr. Han Yuewei (“**Mr. Han**”) has resigned as the chairman of the Board, a non-executive Director and the chairman of the nomination committee of the Company (the “**Nomination Committee**”) due to other work arrangements. Mr. Han has confirmed that he has no disagreement with the Board and there are no matters in relation to his resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its gratitude and appreciation to Mr. Han for his invaluable contributions to the Company and the Board.

APPOINTMENT OF CHAIRMAN OF THE BOARD AND CHAIRMAN OF THE NOMINATION COMMITTEE, AND RESIGNATION OF CHIEF EXECUTIVE OFFICER AND MEMBER OF THE CORPORATE GOVERNANCE COMMITTEE

The Board announces that, with effect from 29 August 2024, Mr. Bai Xiaosong (“**Mr. Bai**”), currently an executive Director and chief executive officer of the Company (“**Chief Executive Officer**”), has been appointed as the chairman of the Board and the chairman of the Nomination Committee, and has resigned as the Chief Executive Officer and a member of the corporate governance committee of the Company (the “**Corporate Governance Committee**”).

Mr. Bai Xiaosong, aged 53, was appointed as an executive Director and Chief Executive Officer, the chairman of the executive committee of the Company, a member of the corporate governance committee of the Company and an authorized representative of the Company under Rule 3.05 of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) in January 2022. Mr. Bai currently serves as a director of China Resources Sanjiu Medical & Pharmaceutical Company Limited (“**CR Sanjiu**”, a subsidiary of the Company, the shares of which are listed on the Shenzhen Stock Exchange (Stock Code: 000999)) and China Resources Double-Crane Pharmaceutical Co., Ltd (“**CR Double-Crane**”, a subsidiary of the Company, the shares of which are listed on the Shanghai Stock Exchange (Stock Code: 600062)), the chairman and a director of Dong-E-E-Jiao Company Limited (a subsidiary of the Company, the shares of which are listed on the Shenzhen Stock Exchange (Stock Code: 000423)). Mr. Bai served as a vice president of CR Sanjiu from June 2021 to December 2021. He served as an assistant general manager of China Resources Snow Breweries (China) Co., Ltd. (華潤雪花啤酒(中國)有限公司) (“**CR Snow Breweries**”) from March 2016 to October 2018 and served as a deputy general manager of CR Snow Breweries from October 2018 to June 2021. He also served as an associate president of CR Double-Crane, a human resources and development controller and a deputy general manager of China Resources Shenyang Sanyo Compressor Co., Ltd. (瀋陽華潤三洋壓縮機有限公司), a sales director of China Resources (Holdings) Company Limited. Mr. Bai holds a bachelor’s degree in Engineering (Petroleum Processing) from Fushun Petroleum Institute, Department of Petrochemical Engineering and a master’s degree of Economics in Finance from Peking University, School of Economics.

There is no service contract entered into between Mr. Bai and the Company for his position as an executive Director. He has no fixed term of service with the Company. Mr. Bai will be subject to retirement by rotation and re-election at the annual general meetings of the Company pursuant to the articles of association of the Company. Mr. Bai will not receive any director’s emolument from the Company. His remuneration will be determined with reference to his position and level of responsibilities, the remuneration policy of the Company and the prevailing market conditions.

Pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”), as at the date of this announcement, Mr. Bai beneficially owned 200,000 shares of the Company. Saved as disclosed above, Mr. Bai does not have any interests in the shares of the Company and its associated corporations within the meaning of Part XV of the SFO.

Save as disclosed above, Mr. Bai have confirmed that (i) he has and had no other relationships with any Directors, senior management or substantial or controlling shareholders of the Company; (ii) he does not currently hold any other position with the Company or any of its subsidiaries; (iii) he did not hold any directorship in other Hong Kong or overseas listed public companies in the last three years; (iv) there are no other matters relating to the aforesaid appointment that need to be brought to the attention of holders of securities of the Company; and (v) there is no other information relating to the aforesaid appointment to be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Listing Rules.

The Board takes this opportunity to extend a warm welcome to Mr. Bai for his new appointments.

APPOINTMENT OF MEMBER OF THE CORPORATE GOVERNANCE COMMITTEE

The Board further announces that, with effect from 29 August 2024, Ms. Deng Rong (“**Ms. Deng**”), currently an executive Director and the chief financial officer of the Company (the “**Chief Financial Officer**”), has been appointed as a member of the Corporate Governance Committee.

The Board takes this opportunity to extend a warm welcome to Ms. Deng for her new appointment.

NON-COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

Notwithstanding the resignation of Mr. Bai as the Chief Executive Officer, he will assume the interim duties and responsibilities of the Chief Executive Officer. Pursuant to Code provision C.2.1 of Part 2 of the Corporate Governance Code as set out in Appendix C1 to the Listing Rules, the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. Notwithstanding the deviation from code provision C.2.1, the Board believes that with the support of the management, vesting the duties and responsibilities of both chairman of the Board and Chief Executive Officer by the same person can facilitate execution of the Group’s business strategies and boost effectiveness of its operation. In addition, under the supervision by the Board which currently consists of three executive Directors, four non-executive Directors and four independent non-executive Directors, the interest of the Shareholders will be adequately and fairly represented. In order to comply with code provision C.2.1, the Company is endeavouring to identify suitable candidate(s) with appropriate professional qualifications or relevant expertise to be appointed as the Chief Executive Officer as soon as practicable. The Company will make further announcement(s) in relation to the above matters as and when appropriate.

By order of the Board
China Resources Pharmaceutical Group Limited
Bai Xiaosong
Chairman

Hong Kong, 29 August 2024

As at the date of this announcement and after the aforesaid changes, the Board comprises Mr. Bai Xiaosong as chairman and executive Director; Mr. Tao Ran and Mdm. Deng Rong as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.